Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer
| Autor: | Verweij, J., Wanders, J., Nielsen, A. L., Pavlidis, Nicholas, Calabresi, F., Huinink, W. T. B., Bruntsch, U., Piccart, M., Franklin, H. R., Kaye, Stanley B. |
|---|---|
| Přispěvatelé: | Pavlidis, Nicholas [0000-0002-2195-9961] |
| Jazyk: | angličtina |
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Adolescent Ovary cancer Liver toxicity Vomiting Major clinical study Follow-up studies Article Ovarian neoplasms Colorectal neoplasms Nonsmall cell lung Breast cancer Lung neoplasms Antibiotics Neoplasms Breast Phase 2 clinical trial Aged Priority journal Aminoglycoside Carcinoma Non-small-cell lung Ovary Drug administration schedule Nausea Colorectal cancer Antineoplastic Colorectum Middle age Phase ii Clinical trial Elsamicin a Elsamitrucin Lung non small cell cancer Female Intravenous drug administration Breast neoplasms Malaise Human |
| Zdroj: | Annals of Oncology |
| Popis: | Purpose: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. Patients and methods: Eligibility required histologically proven cancer. Patients with colorectal or non-small cell lung cancer could not have received prior chemotherapy. Patients were entered if WHO PS was ≤2 and organ functions were normal. Treatment consisted of Elsamitrucin 25 mg/m2/week given as a 5-10 min infusion for at least 3-6 weekly doses. Results: One hundred and five patients entered the studies, 97 were eligible, 94 are evaluable for toxicity and 75 for response. Toxicity mainly consisted of mild nausea/vomiting, and less frequently reversible hepatotoxicity and malaise. No objective responses were seen. Conclusion: Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer. © 1994 Kluwer Academic Publishers. 5 4 375 376 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|